Recipharm opens new GMP suite for clinical trial material
Recipharm | June 07, 2017
The suite, which represents a $750k investment, is intended to produce CTM for clinical studies up to Phase II for non-sterile dosage forms, including metered dose inhalers and semi-solid topical products.